Retatrutide · research summary

Advances in the management of obesity: non-pharmacological strategies, herbal formulations, current pharmacotherapy, emerging drugs, and future perspectives.

Frontiers in endocrinology · 2026. Summary drawn from the study's full text. Each statement is followed by the exact sentence it comes from. This is a research summary, not medical advice.

Study type

Narrative review of obesity pharmacotherapy
“This review provides the current understanding of obesity pharmacotherapy, discusses approved anti-obesity medications, highlights emerging therapeutic agents and drugs under clinical development, and explores future perspectives in obesity management.”

Subjects

Adults with obesity or overweight
“Pharmacotherapy is an adjunct to lifestyle modification for adults with a body mass index (BMI) ≥30 kg/m² or ≥27 kg/m² in the presence of comorbidities such as type 2 diabetes mellitus, hypertension, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease (13, 15).”

Duration

Literature search covered studies published between January 2015 and June 2026
“A comprehensive literature search was performed using PubMed, Scopus, Embase, Web of Science, ClinicalTrials.gov, and Google Scholar for studies published between January 2015 and June 2026.”

Reported findings

Incretin-based therapies, particularly GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists, have demonstrated unprecedented efficacy in achieving clinically meaningful and sustained weight loss.
“Recent advances in obesity pharmacology have revolutionised treatment strategies, particularly with the introduction of incretin-based therapies such as glucagon-like peptide-1 (GLP-1) receptor agonists and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists, which have demonstrated unprecedented efficacy in achieving clinically meaningful and sustained weight loss.”
Tirzepatide produced a least-squares mean weight reduction of 20.2% at 72 weeks, which was superior to semaglutide in a head-to-head trial.
“In the SURMOUNT-5 trial, tirzepatide produced a least-squares mean weight reduction of 20.2% at 72 weeks, compared with 13.7% with semaglutide, demonstrating superior weight reduction with tirzepatide in adults with obesity without type 2 diabetes (97).”
Emerging triple agonists like retatrutide have shown substantial weight reduction, with participants achieving a mean weight loss of 28.3% at 80 weeks in phase III trials.
“Subsequently, phase III evidence from the TRIUMPH-1 trial demonstrated substantially greater weight reduction, with participants receiving retatrutide 12 mg achieving a mean weight loss of 28.3% at 80 weeks.”

Source: PubMed 42769318 · DOI 10.3389/fendo.2026.1933913 · all study summaries

Study type

Narrative review of obesity pharmacotherapy

“This review provides the current understanding of obesity pharmacotherapy, discusses approved anti-obesity medications, highlights emerging therapeutic agents and drugs under clinical development, and explores future perspectives in obesity management.”

Subjects

Adults with obesity or overweight

“Pharmacotherapy is an adjunct to lifestyle modification for adults with a body mass index (BMI) ≥30 kg/m² or ≥27 kg/m² in the presence of comorbidities such as type 2 diabetes mellitus, hypertension, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease (13, 15).”

Reported findings

Incretin-based therapies, particularly GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists, have demonstrated unprecedented efficacy in achieving clinically meaningful and sustained weight loss.

“Recent advances in obesity pharmacology have revolutionised treatment strategies, particularly with the introduction of incretin-based therapies such as glucagon-like peptide-1 (GLP-1) receptor agonists and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists, which have demonstrated unprecedented efficacy in achieving clinically meaningful and sustained weight loss.”

Tirzepatide produced a least-squares mean weight reduction of 20.2% at 72 weeks, which was superior to semaglutide in a head-to-head trial.

“In the SURMOUNT-5 trial, tirzepatide produced a least-squares mean weight reduction of 20.2% at 72 weeks, compared with 13.7% with semaglutide, demonstrating superior weight reduction with tirzepatide in adults with obesity without type 2 diabetes (97).”

Emerging triple agonists like retatrutide have shown substantial weight reduction, with participants achieving a mean weight loss of 28.3% at 80 weeks in phase III trials.

“Subsequently, phase III evidence from the TRIUMPH-1 trial demonstrated substantially greater weight reduction, with participants receiving retatrutide 12 mg achieving a mean weight loss of 28.3% at 80 weeks.”